Compare FLEX & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLEX | EXAS |
|---|---|---|
| Founded | 1990 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.7B | 19.6B |
| IPO Year | 1994 | N/A |
| Metric | FLEX | EXAS |
|---|---|---|
| Price | $64.21 | $103.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 19 |
| Target Price | $60.00 | ★ $84.27 |
| AVG Volume (30 Days) | ★ 3.9M | 2.4M |
| Earning Date | 02-04-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.23 | N/A |
| Revenue | ★ $26,835,000,000.00 | $3,082,033,000.00 |
| Revenue This Year | $7.16 | $19.40 |
| Revenue Next Year | $6.15 | $13.54 |
| P/E Ratio | $28.67 | ★ N/A |
| Revenue Growth | 4.89 | ★ 14.47 |
| 52 Week Low | $25.11 | $38.81 |
| 52 Week High | $72.22 | $103.42 |
| Indicator | FLEX | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 46.61 | 74.02 |
| Support Level | $55.16 | $102.13 |
| Resistance Level | $66.19 | $102.56 |
| Average True Range (ATR) | 3.44 | 0.32 |
| MACD | -0.50 | -0.26 |
| Stochastic Oscillator | 52.15 | 100.00 |
Flex Ltd is a contract manufacturing company providing comprehensive electronics design, manufacturing, and product management services to electronics and technology companies. The company's operating segments include Flex Agility Solutions (FAS) and Flex Reliability Solutions (FRS). Flex Agility Solutions segment includes markets such as Communications, Enterprise and Cloud; Lifestyle; and Consumer Devices. Flex Reliability Solutions segment includes markets such as Automotive, Health Solutions, and Industrial.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.